Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > AZD 6244 CAS 606143-52-6 Selumetinib ARRY 142886

AZD 6244 CAS 606143-52-6 Selumetinib ARRY 142886 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C17H15BrClFN4O3
Production Capacity: 100 KG/YEAR
Delivery Date: within 7 days
Molecular Weight: 457.68
Specification: CP/USP/EP
Means of Transport: Ocean,Land,Air
Packing: As per request of clients
Molecular Formula: C17H15BrClFN4O3
Content: 98%min
Appearance: white powder
CAS: 606143-52-6

Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC).

AZD 6244 ( CAS: 606143-52-6 )



Molecular Formula


Molecular Weight






Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC).

Mechanism of action

The gene BRAF is part of the MAPK/ERK pathway, a chain of proteins in cells that communicates input from growth factors. Activating mutations in the BRAF gene, primarily V600E (meaning that the amino acid valine in position 600 is replaced by glutamic acid), are associated with lower survival rates in patients with papillary thyroid cancer. Another type of mutation that leads to undue activation of this pathway occurs in the gene KRAS and is found in NSCLC. A possibility of reducing the activity of the MAPK/ERK pathway is to block the enzyme MAPK kinase (MEK), immediately downstream of BRAF, with the drug selumetinib. More specifically, selumetinib blocks the subtypes MEK1 and MEK2 of this enzyme.

Possible uses

In addition to thyroid cancer, BRAF-activating mutations are prevalent in melanoma (up to 59%), colorectal cancer (5–22%), serous ovarian cancer(up to 30%), and several other tumor types.

Selumetinib has also been shown to inhibit growth of GNAQ mutated uveal melanoma cell lines. Furthermore, preliminary results suggest that selumetinib treatment of uveal melanoma patients can result in tumor shrinkage as the consequence of sustained inhibition of ERK phosphorylation.

KRAS mutations appear in 20 to 30% of NSCLC cases and about 40% of colorectal cancer.

A Phase II clinical trial about selumetinib in NSCLC has been completed in September 2011; one about cancers with BRAF mutations is ongoing as of June 2012.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: